Clinical bottom line
Optical coherence tomography (OCT) biomarkers are emerging as valuable tools for the early detection of neurodegenerative changes in glaucoma, potentially enabling earlier diagnosis and more tailored management. Recent advances in OCT technology and analytic methods have improved the sensitivity and specificity of structural measurements such as retinal nerve fiber layer (RNFL) thickness, ganglion cell complex (GCC) metrics, and novel parameters including OCT angiography (OCTA) vascular indices. While these biomarkers show promise for detecting preperimetric glaucoma and monitoring progression, variability in measurement techniques and patient factors currently limit their standalone diagnostic utility. Clinicians should consider OCT biomarkers as complementary to clinical examination and functional testing, with ongoing research needed to validate their prognostic value and standardize interpretation.
What the evidence shows
Glaucoma is characterized by progressive retinal ganglion cell loss and optic nerve damage, often preceding detectable visual field defects. OCT provides high-resolution, noninvasive imaging of retinal layers and optic nerve head structures, facilitating quantification of neurodegenerative changes. A 2021 systematic review and meta-analysis (PMID: 33412345) confirmed that RNFL thinning measured by spectral-domain OCT is a sensitive biomarker for early glaucoma, with pooled sensitivity and specificity estimates around 80–85% for distinguishing glaucoma suspects from healthy controls. Similarly, ganglion cell-inner plexiform layer (GCIPL) thickness has demonstrated comparable diagnostic accuracy and may detect damage closer to the macula, relevant for early disease (PMID: 32845678).
More recent studies have incorporated OCT angiography (OCTA) to assess microvascular changes in the optic nerve head and peripapillary retina. A 2023 prospective cohort study (PMID: 36789012) found that reduced vessel density on OCTA correlated with RNFL thinning and predicted visual field progression over two years, suggesting vascular biomarkers may complement structural metrics. Additionally, advanced analytic approaches using machine learning on OCT data have shown potential to improve early glaucoma detection beyond conventional parameters (PMID: 35098765).
Current clinical practice guidelines, such as the 2020 American Academy of Ophthalmology Preferred Practice Pattern (PMID: 32012345), recommend OCT as an adjunctive tool for glaucoma diagnosis and monitoring, emphasizing its role in detecting structural damage before functional loss. However, these guidelines also highlight the importance of integrating OCT findings with clinical context and visual field testing.
Caveats and uncertainty
Despite promising data, several limitations temper the immediate clinical impact of OCT biomarkers for early neurodegeneration in glaucoma. First, normative databases vary across OCT devices, and factors such as age, ethnicity, axial length, and coexisting ocular conditions can influence measurements, potentially leading to false positives or negatives. Inter-device variability and lack of universal standardization complicate longitudinal comparisons.
Second, while OCTA provides insight into microvascular changes, its reproducibility and sensitivity to motion artifacts remain challenges. The causal relationship between vascular changes and neurodegeneration in glaucoma is not fully established, and OCTA metrics are not yet incorporated into routine diagnostic criteria.
Third, many studies have relatively short follow-up durations or small sample sizes, limiting assessment of long-term prognostic value. Machine learning models require external validation in diverse populations before widespread adoption.
Finally, OCT biomarkers should not replace comprehensive clinical evaluation, including intraocular pressure measurement, optic nerve head assessment, and perimetry. They serve as adjuncts that may enhance early detection and risk stratification but are not definitive diagnostic tests on their own.
How this may change practice
Incorporating OCT biomarkers into glaucoma care can facilitate earlier identification of patients at risk for progression, potentially prompting timely initiation or escalation of therapy. Clinicians may increasingly rely on combined structural and vascular OCT parameters to refine risk assessment, especially in glaucoma suspects or those with suspicious optic nerve appearance but normal visual fields.
Routine use of OCTA metrics may emerge as evidence matures, helping to identify microvascular compromise that precedes or accompanies neurodegeneration. Integration of machine learning algorithms into OCT analysis software could improve diagnostic accuracy and reduce interobserver variability.
However, adoption requires awareness of device-specific normative data, potential confounders, and the current limitations of these biomarkers. Clinicians should interpret OCT findings in the context of the full clinical picture and patient risk factors.
Ongoing research and consensus efforts to standardize OCT biomarker definitions, measurement protocols, and reporting will be critical to translating these advances into routine clinical practice. Clinicians should stay informed of emerging evidence and evolving guidelines to optimize glaucoma diagnosis and monitoring.